Activist investor Starboard Value takes stake in consumer products maker Kenvue, sources say
Activist investor Starboard Value has a stake in Kenvue , which makes Listerine and Tylenol, two sources familiar with the matter told Reuters on Sunday.
Activist Starboard Value Takes Stake in Tylenol-Maker Kenvue
Starboard wants Kenvue, which was spun out of Johnson & Johnson last year and has a market value of over $40 billion, to make changes to boost its share price.
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.
Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?
Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Kenvue: Turning Cautious On The Stock While Remaining Optimistic On The Business
Just like trying to catch falling knives, chasing stocks can be a dangerous endeavor. In this update, I share my latest thoughts on Kenvue stock, focusing specifically on the Q2 2024 results that sent the stock soaring 25%. I've incorporated the latest results into my valuation model and explain what the market is currently pricing in for KVUE stock.
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Kenvue Inc. KVUE — the parent company of well-known pharmacy items like Listerine, Mylanta, and Tylenol — is showing a bullish pattern on the charts Tuesday.
Kenvue: Promising Steps Toward Long-Term Success
Kenvue's share price recently spiked as a result of a strong second quarter earnings report. Kenvue's strong brands continued to gain market shares, showing progress despite challenges in the consumer environment. Strong brand performance with growth in well-known products like Listerine, Tylenol, Zyrtec, and Benadryl.
Kenvue Goes Boom - Now What?
Johnson & Johnson spun off its consumer segment into Kenvue, a $40 billion company in the consumer defensive sector. Kenvue operates in three main segments, including well-known brands like Tylenol, Neutrogena, and Listerine, with a global sales distribution. Despite recent underperformance, Kenvue saw a 14% stock price rally after reporting 2Q24 earnings, beating market expectations and showing signs of optimism.
S&P 500 Gains and Losses Today: Kenvue Soars on Band-Aid Maker's Strong Outlook
Major U.S. equities indexes rebounded on Tuesday following three turbulent days of trading that saw heightened levels of economic uncertainty send stocks tumbling.
Kenvue Inc. (KVUE) Q2 2024 Earnings Call Transcript
Kenvue Inc. (NYSE:KVUE ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Jim Giannakouros - Interim Head, Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Anna Lizzul - BofA Securities, Inc. Steve Powers - Deutsche Bank Securities, Inc. Andrea Teixeira - JPMorgan Securities LLC Nik Modi - RBC Capital Markets LLC Filippo Falorni - Citigroup Global Markets, Inc. Susan Anderson - Canaccord Genuity Jeremy Fialko - HSBC Peter Grom - UBS Operator Hello and welcome to the Kenvue Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Band-Aid, Tylenol Parent Kenvue Reports Healthy Full-Year Guidance
Kenvue (KVUE) shares surged in intraday trading Tuesday after the company affirmed its full-year guidance that topped analysts' expectations.
